BioNexus Gene Lab
BGLC
5 hedge funds and large institutions have $171K invested in BioNexus Gene Lab in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.12% more ownership
Funds ownership: 0% → 0.12% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$97.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$84.3K |
| 3 |
HF
HRT Financial
New York
|
+$74K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$37.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $50K | +$97.2K | +5,969 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $43.5K | +$84.3K | +5,175 | New |
|
|
HF
3
HRT Financial
New York
| $38K | +$74K | +4,547 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $20K | +$37.4K | +2,299 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $19.9K | +$38.6K | +2,368 | New |
|
BGLC Hedge Fund Activity: Q3 2023 in Review
5 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q3 2023, worth a combined $171K.
Buyers outnumbered sellers: 5 funds opened new BGLC positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $97.2K.
- 5 institutional investors held BioNexus Gene Lab (BGLC) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $171K of BioNexus Gene Lab stock for Q3 2023.
- 5 funds opened new BioNexus Gene Lab positions in Q3 2023 and 0 closed out, a net change of +5 holders.
- The largest BioNexus Gene Lab buyer in Q3 2023 was Virtu Financial, an estimated $97.2K added.
Based on aggregated 13F filings for Q3 2023.